​
Understanding the difference between GLP and non-GLP studies is essential for building a strong preclinical strategy. Study design, QA oversight, and documentation standards can directly affect regulatory readiness and downstream development risk.
This article breaks down how GLP changes operational expectations in efficacy and safety studies, and why the distinction matters during IND-enabling development. Read the full article here
#GLP #PreclinicalResearch #DrugDevelopment #TranslationalResearch #Biotech
In Vivo Disease Model: Reduce Late-Stage Risk with the Right Translational Choice
​
Late-stage failures often begin with poor translational alignment in preclinical research. Choosing the right in vivo disease model can improve predictive value and strengthen development decisions earlier in the pipeline.
Learn how translational model selection helps reduce risk and support more clinically relevant outcomes. Read the full article here.
#PreclinicalResearch #DrugDevelopment #TranslationalScience #InVivoModels #Biotech